Currently Viewing:
American Heart Association Scientific Sessions 2019
Kiersten Combs Discusses Findings of the DAPA-HF Study in Population Without Diabetes
November 17, 2019
Dr Jay Edelberg Outlines the Clinical Burdens and Treatment Options for Hypertrophic Cardiomyopathy
November 17, 2019
Details of DAPA-HF Results Point to Dapagliflozin for Some Heart Failure Patients Without Diabetes
November 17, 2019
In Stable Heart Disease, Study Finds Stents Might Be No Better Than Drugs
November 17, 2019
Dapagliflozin Meets Quality-of-Life Marks, Efficacy Among Seniors, Data Show
November 17, 2019
From Self-Reporting Accuracy to Therapy Access: AHA Posters Cover Issues in Disparities
November 18, 2019
Dr John Pfeifer Outlines Necessary Steps for Preventive Action in Patients With Atrial Fibrillation
November 18, 2019
Sara Levintow Analyzes 2013 ACC/AHA Cholesterol Guidelines in Relation to Trends in US Lipid Testing
November 18, 2019
Plaques May Be Key to Vascepa's Role in Preventing CV Events
November 18, 2019
48-Week Results for Mavacamten Draw Crowd at AHA Session
November 19, 2019
Dr Vinay Kini Discusses the Growing Influence of the EHR in the Transition to Value-Based Care
November 19, 2019
Dr Stephen Heitner Details the Significance of the PIONEER-OLE Study in Treating Obstructive HCM
November 19, 2019
Dr Stephen Heitner Outlines the Next Steps After MAVERICK-HCM Study Findings
November 21, 2019
Dr Stephen Voyce Details Innovations and Preventive Strategies in Detection of Atrial Fibrillation
November 24, 2019
Dr Brent Williams Discusses Study Findings on Detection of Atrial Fibrillation
November 27, 2019
Dr Brandon Fornwalt Discusses the Preventive Efficacy of AI in Monitoring for Atrial Fibrillation
November 30, 2019
Dr Douglas Losordo Discusses the Evolution and Importance of CD34+ Treatment in Patients With CMD
December 04, 2019
Dr Brian Ghoshhajra Details the Significance of the PDS-2 System in Affecting Progression of HoFH
December 05, 2019
Dr Roland Chen Outlines the GUARD-AF Trial as a Preventive Mechanism in Reducing Risk of Stroke
December 06, 2019
Currently Reading
Dr Darryl Sleep: Identifying and Treating Elevated LDL-C in Patients Can Mitigate Heart Attack Risk
December 06, 2019
Dr Javed Butler Discusses Why People With Diabetes Are at Greater Risk of Heart Failure
January 11, 2020
Dr Jay Edelberg Discusses PIONEER-OLE and Design of EXPLORER-HCM in Patients With Obstructive HCM
January 16, 2020
Dr Jay Edelberg Explains Preventive Efficacy and Potential FDA Approval of Mavacamten
January 26, 2020
Dr Roland Chen Discusses the Primary Endpoints of the GUARD-AF Trial for Atrial Fibrillation
January 31, 2020

Dr Darryl Sleep: Identifying and Treating Elevated LDL-C in Patients Can Mitigate Heart Attack Risk

Identifying elevated LDL-C levels in patients and treating them with evolocumab can potentially mitigate and reduce the rate of ischemic events, said Darryl Sleep, MD, senior vice president, global medical and chief medical officer at Amgen.


Identifying elevated LDL-C levels in patients and treating them with evolocumab can potentially mitigate and reduce the rate of ischemic events, said Darryl Sleep, MD, senior vice president for global medical and chief medical officer at Amgen.

Transcript

Can you discuss the significance of the evolocumab FOURIER clinical trial findings and their impact on patients in lowering high LDL-C and subsequent risk of myocardial infarction?

Patients post-myocardial infarction are at significant risk for developing additional ischemic heart disease or myocardial infarction. This is 1 of those areas where it's been clearly identified as a risk factor, and LDL-C is an easily measured biomarker that clearly demonstrates increased risk as well. So, what we've done in the FOURIER study is really identify in this analysis those patients that have had a recent myocardial infarction within the first year of the infarction with elevated LDL-C that number 1, the closer you are to the index event, the more likely you are to have a subsequent event. Elevated LDL-C clearly puts you at risk for that subsequent event and [through] aggressive treatment of patients with elevated LDL-C in that setting, you can actually mitigate, reduce the events, and the rate of events in those patients. So, perfect interface between identifiable marker in patients at risk, a treatment option that can lower LDL-C significantly, and importantly, that reduces the event that you're seeking to prevent.

 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up